Hansoh Pharmaceutical (3692) Nyanmɛn Kpɛn
AI bɛ́nɛ́nɛ́: 3692
AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.
Prix su les 6 mois derniers
Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.
Yɛ́lɛ́ Premium🔒 Nzɛnkan nyinmɛn
Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.
Yɛ́lɛ́ PremiumNyanmiɛn nɛnɛn
Hansoh Pharmaceutical is among the top 30 pharmaceutical companies in China. The company manufactures medicines and has 20 years of experience in research for the treatment of diseases, including cancer, diabetes, and nervous system disorders. By the end of 2020, the company had carried out more than 50 national research and development projects and obtained over 300 invention patents in China and abroad. It owns R&D centers in Shanghai, Changzhou, and Lianyungang (China), as well as in Maryland (United States).
